RegeneRx Biopharmaceuticals, Inc.

RGRX

US75886X3061

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 15:14:15 2024-06-06 EDT			5-day change	1st Jan Change
0.0522 ^USD	+3,628.57%		+3,628.57%	+4,250.00%

2023	RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	CI
2023	RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	CI

Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

March 02, 2021 at 04:10 pm

RegeneRx Biopharmaceuticals, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 76,761 compared to USD 76,762 a year ago. Operating loss was USD 1.294 million compared to USD 1.261 million a year ago. Net loss was USD 1.523 million compared to USD 1.404 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	23-07-02	CI
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	23-06-12	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-11	CI
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-04-10	CI
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy	23-01-31	CI
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	23-01-03	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Regenerx Licensee Submits Special Protocol Assessment to Fda for 4Th Phase 3 Clinical Trial for Dry Eye Disease	22-10-24	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
RegeneRx Biopharmaceuticals, Inc. Reports that Researchers Demonstrate the Therapeutic Efficacy of Thymosin Beta 4	22-05-04	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury	22-01-25	CI
RegeneRx Biopharmaceuticals, Inc. Announces U.S. FDA Accepts Request for Pre-BLA meeting Pursuant to RGN-259	21-12-17	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
RegeneRx Biopharmaceuticals, Inc. Announces Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting	21-10-29	CI
RegeneRx Biopharmaceuticals, Inc. Announces New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease	21-10-05	CI
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-06	CI
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome	21-07-14	CI
RegeneRx Biopharmaceuticals, Inc. announced that it has received $1.98 million in funding	21-06-29	CI
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $2 million in funding	21-06-27	CI
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
RegeneRx Biopharmaceuticals, Inc. Reports Topline Results of ARISE-3 Dry Eye Trial	21-03-18	CI

Chart RegeneRx Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The Company's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. The Company's RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. Its RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
REGENERX BIOPHARMACEUTICALS, INC.	+4,250.00%	78.75K
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
BIOGEN INC.	-12.88%	32.82B
UCB	+64.77%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.32B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
ALTEOGEN INC.	+173.10%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	9.06B